{"analyses":[{"ciLowerLimit":"2.007","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"9.656","estimateComment":"KdD/Kd","groupDescription":"Odds ratios and corresponding 95% CIs were estimated by a stratified analysis using the Mantel-Haenszel method.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Odds Ratio (OR)","paramValue":"4.403"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.3","upperLimit":"10.0","value":"5.2"},{"groupId":"OG001","lowerLimit":"14.1","upperLimit":"23.0","value":"18.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"154"},{"groupId":"OG001","value":"312"}],"units":"Participants"}],"description":"MRD\\[-\\] at 12-month was defined as achievement of MRD\\[-\\] status as assessed by next-generation sequencing (NGS; at a 10\\^-5 level) at the 12 months landmark (from 8 months to 13 months window).\n\n95% confidence intervals (CIs) for proportions were estimated using the Clopper-Pearson method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Carfilzomib was administered intravenously (IV) at 20 mg/m\\^2 in Cycle 1: days 1 and 2; at 56 mg/m\\^2 in Cycle 1: days 8, 9, 15 and 16. The 56 mg/m\\^2 dosage was continued in Cycles 2+ on days 1, 2, 8, 9, 15 and 16.\n\nDexamethasone was taken by IV infusion at 20 mg on Cycle 1, days 1 and 2 (in Cycles 2+, days 1 and 2 could be either oral or IV) and either orally or by IV infusion on days 8, 9, 15 and 16 and at 40 mg on day 22 of all 28-day cycles.","id":"OG000","title":"Kd - Carfilzomib and Dexamethasone"},{"description":"Carfilzomib was administered intravenously (IV) at 20 mg/m\\^2 in Cycle 1: days 1 and 2; at 56 mg/m\\^2 in Cycle 1: days 8, 9, 15 and 16. The 56 mg/m\\^2 dosage was continued in Cycles 2+ on days 1, 2, 8, 9, 15 and 16.\n\nDexamethasone was taken by IV infusion at 20 mg on Cycle 1, days 1 and 2 (in Cycles 2+, days 1 and 2 could be either oral or IV) and either orally or by IV infusion on days 8, 9, 15 and 16 and at 40 mg on day 22 of all 28-day cycles. The administration of dexamethasone was given on carfilzomib and/or daratumumab IV infusion days.\n\nDaratumumab was administered by IV at 8 mg/kg on Cycle 1: days 1 and 2; at 16 mg/kg on Cycle 1: days 8, 15 and 22, and Cycle 2: days 1, 8, 15, and 22. The 16 mg/kg dosage was continued on Cycles 3-6: days 1 and 15. The 16 mg/kg dosage was continued on Cycles 7+: day 1 only.","id":"OG001","title":"KdD - Carfilzomib, Dexamethasone and Daratumumab"}],"paramType":"NUMBER","populationDescription":"Intent to Treat Population","reportingStatus":"POSTED","timeFrame":"12 Months (8- to 13-month window)","title":"Percentage of Participants Who Achieved Minimal Residual Disease Negative (MRD[-]) Status as Assessed by Next Generation Sequencing at 12 Months","type":"SECONDARY","unitOfMeasure":"percentage of participants"}